growth hormone therapy refers use growth hormone gh prescription one form hormone therapy growth hormone peptide hormone secreted pituitary gland stimulates growth cell reproduction past growth hormone extracted human pituitary glands growth hormone produced recombinant dna technology prescribed variety reasons gh therapy focus social ethical controversies years article describes history gh treatment current uses risks arising gh use articles describe gh physiology diseases gh excess acromegaly pituitary gigantism deficiency recent phenomenon hgh controversies growth hormone sports growth hormone cows growth hormone deficiency treated replacing growth lonapegsomatropin approved medical use united states august endocrine society recommended adult patients diagnosed growth hormone deficiency ghd administered individualized gh treatment respect diagnosis guidelines state adults patients structural hypothalamicpituitary disease surgery irradiation areas head trauma evidence pituitary hormone deficiencies considered evaluation acquired ghd idiopathic ghd adults rare stringent criteria necessary make diagnosis absence suggestive clinical circumstances significant falsepositive error rate response single gh stimulation test suggest use two tests making gh replacement therapy provide number measurable benefits ghdeficient include improved bone increased muscle mass decrease adipose tissue faster hair nail growth strengthened immune system increased circulatory system improved blood lipid levels long term mortality benefit yet peerreviewed article published indicates growth hormone gh replacement unequivocally benefits growth body composition cardiovascular risk factors quality life less known effects gh learning gh approved us food drug administration treatment conditions new england journal medicine published two editorials expressing concern offlabel uses hgh proliferation advertisements hghreleasing dietary supplements emphasized evidence use hgh healthy adults geriatric patients safe effective especially emphasized risks longterm hgh treatment unknown one editorial jeffrey drazen md editorinchief mary lee vance provided nejms editorial original cautious comment much cited study use hgh geriatric patients low growth hormone levelscitation needed small controlled study gh given severely ill adults intensive care unit setting purpose increasing strength reducing muscle wasting critical illness showed higher mortality rate patients received reason unknown gh rarely used icu patients unless severe growth hormone deficiencycitation needed gh treatment usually decreases insulin studies showed evidence increased diabetes incidence ghtreated adult hypopituitary past believed gh treatment could increase cancer risk large study recently concluded relatively short followup overall primary cancer risk patients receiving gh adults increased elevated sirs risk getting cancer found subgroups usa cohort defined age years childhood onset gh fda issued safety communication august stating evidence regarding recombinant human growth hormone increased risk death inconclusive reviewing sources including french study compared persons certain kinds short stature idiopathic growth hormone deficiency idiopathic gestational short stature treated recombinant human growth hormone childhood followed long period time individuals general population perhaps famous person exemplified appearance untreated congenital growth hormone deficiency charles sherwood stratton exhibited p barnum general tom thumb married lavinia warren pictures couple show typical adult features untreated severe growth hormone deficiency despite severe shortness limbs trunks proportionalcitation needed middle twentieth century endocrinologists understood clinical features growth hormone deficiency gh protein hormone like insulin purified pig cow pancreases treatment type diabetes since however pig cow gh work humans due greater speciestospecies variation molecular structure ie insulin considered evolutionarily conserved ghcitation needed extracted growth hormone used since late late use replaced recombinant ghcitation needed late maurice raben purified enough gh human pituitary glands successfully treat ghdeficient boy endocrinologists began help parents severely ghdeficient children make arrangements local pathologists collect human pituitary glands removal autopsy parents would contract biochemist purify enough growth hormone treat child families could manage complicated undertakingcitation needed national pituitary agency formed branch us national institutes health purpose agency supervise collection human pituitary glands autopsies performed arrange largescale extraction purification gh distribute limited number pediatric endocrinologists treating ghdeficient children research protocols canada uk australia new zealand france israel countries establish similar governmentsponsored agencies collect pituitaries purify gh distribute treatment severely ghdeficient childrencitation needed supplies cadaver growth hormone limited severely deficient children treated children us children worldwide given gh extracted human pituitary glands treat severe gh deficiency physicians trained relatively new specialty pediatric endocrinology provided care late hundred physicians dozen largest university medical centers around worldcitation needed npa gh extraction purification procedure refined improvedcitation needed shortage available cadaver gh worsened late autopsy rate us declined number pediatric endocrinologists able diagnose treat gh deficiency increased gh rationed often treatment would stopped child reached arbitrary minimal height ft children short reasons severe gh deficiency lied told would benefit treatment pediatric endocrinologists remained university medical centers departments able support research program access npa growth hormone late swedish pharmaceutical company kabi contracted number hospitals europe buy pituitary glands first commercial gh product crescormon although additional source gh welcomed crescormon greeted ambivalence pediatric endocrinologists united states first concern kabi would begin purchase pituitaries us would quickly undermine npa relied donation system like blood transfusioncitation needed number autopsies continued shrink would pathologists sell pituitaries higher bidder second offense kabipharmacias marketing campaign directed primary care physicians slogan determine need implying services specialist needed growth hormone treatment anymore short child might candidate treatment although crescormon controversy us long forgotten kabis pituitary purchase program continued generate scandal europe recently needed new american corporation genentech collaboration kabi developed started trials recombinant human growth hormone rhgh made new technology recombinant dna human genes inserted bacteria could produce unlimited amounts protein new technology approval deferred lengthy safety trials continued next four four young adults us received npa growth hormone developed cjd disease connection recognized within months use human pituitary gh rapidly ceased total cases cjd occurred adults received npa gh comparable numbers cases occurred around world cases people received gh purified improved methodscitation needed discontinuation human cadaver growth hormone led rapid food drug administration approval genentechs recombinant human growth hormone introduced protropin united states although previously scarce commodity suddenly available bucketfuls price treatment per year highest time genentech justified prolonged research development investment orphan drug status pioneering postmarketing surveillance registry tracking safety effectiveness national cooperative growth studycitation needed within years gh treatment become common competitors entered market eli lilly launched competing natural sequence growth hormone humatrope pharmacia formerly kabi pfizer introduced genotropin novo nordisk introduced norditropin serono emd serono introduced saizen serostim ferring introduced zomacton genentech eventually introduced another hgh product nutropin stopped making protropin price competition begun teva primarily generics company introduced tevtropin chinese companies entered market well introduced pricing competition neogenica bioscience ltd introduced hypertropin genescience introduced jintropin anhui anke biotechnology introduced ansomone shanghai united kefei biotechnology introduced kefei hygene biopharm introduced hygetropin recombinant human growth hormone products competed various marketing strategies children severe deficiency developed world likely access pediatric endocrinologist diagnosed offered treatmentcitation needed pediatric endocrinology became recognizable specialty reach board status us late even years later cognitive procedureless specialty dealing mostly rare diseases one smallest lowestpaid obscure medical specialitiescitation needed pediatric endocrinologists physicians interested arcana gh metabolism childrens growthcitation needed previously academic arguments took new practical significance major financial implications major scientific arguments dated back days gh scarcitycitation needed ethical questions new gh wise use finite healthcare resources physicians primary responsibility patient gh given extremely short children make taller definition extremely short simply rise negating expected social benefit gh given short children whose parents afford shortness become permanent mark lower social origins issues outlined ethics section whole meetings devoted questions pediatric endocrinology become specialty bioethics issues despite price became era experimentation see else growth hormone could help medical literature decade contains hundreds reports small trials gh use nearly every type growth failure shortness imaginable cases growth responses modestcitation needed conditions large enough potential market rigorous trials sponsored pharmaceutical companies making growth hormone achieve approval market specific indications turner syndrome chronic kidney failure first nonghdeficient causes shortness receive fda approval gh treatment syndrome intrauterine growth retardation followed similar expansion use occurred europecitation needed one obvious potential market adult gh deficiency several gh companies sponsored publicized research quality life adults severe gh deficiencycitation needed people treated gh childhood severe deficiencycitation needed although injections painless many happy leave injections behind reached final heights lownormal rangecitation needed however adults people children growth hormone deficiency adults growth hormone deficiency share common adult problems reduced physical mental social energy excess adipose diminished muscle diminished libido poor bone density higher cholesterol levels higher rates cardiovascular disease research trials soon confirmed months gh could improve nearly parameters however despite marketing efforts ghdeficient adults remain untreated though gh use slow accepted among adults gh deficiency similar research see gh treatment could slow reverse similar effects aging attracted much public interest publicized trial reported daniel rudman types hormone supplementation aging testosterone estrogen dhea confirmation benefit accurate understanding risks slowly evolving ronald klatz american academy antiaging medicine published grow young hgh amazing medically proven plan reverse effects uncritical touting gh answer time internet amplified proposition spawned hundred frauds scams however adoption hgh term provided easy way distinguish hype evidence growth hormone hit news us fda granted eli lilly approval market humatrope treatment idiopathic short stature indication controversial several reasons primary one difficulty defining extreme shortness normal test results disease rather extreme end normal height recombinant growth hormone available us manufacturers include nutropin genentech humatrope eli lilly company genotropin pfizer norditropin novo nordisk tevtropin teva saizen merck serono products nearly identical composition efficacy cost varying primarily formulations delivery devicescitation needed somapacitanbeco sogroya first onceper week subcutaneous human growth hormone hgh therapy approved united approved medical use united states august growth hormone gh l also called somatotropin british somatotrophin human form growth hormone known human growth hormone hgh ovine growth hormone sheep growth hormone abbreviated ogh gh refer either natural hormone produced pituitary somatotropin biosynthetic gh therapycitation needed cadaver growth hormone term gh extracted pituitary glands human cadavers therapy deficient children us cadaver gh also referred npa growth hormone provided national pituitary agency national programs commercial firms well associated development disease withdrawn usecitation needed rhgh rhgh rhgh refers recombinant human growth hormone somatropin inn amino acid sequence identical endogenous human ghcitation needed coincidental rhgh also refers rhesus monkey gh rhgh using accepted naming convention rh rhesus rhesus growth hormone never used physicians treat human patients rhesus gh part lore underground anabolic steroid community years fraudulent versions may bought sold gymscitation needed metgh refers hormone somatrem inn first recombinant gh product marketed trade name protropin genentech amino acid sequence human gh extra methionine end chain facilitate manufacturing process discontinued rbst refers recombinant bovine somatotropin cow growth hormone recombinant bovine gh rbgh rbgh httpsenwikipediaorgwikigrowthhormonetherapy